Eli Lilly and Company $LLY Stake Boosted by Ameritas Advisory Services LLC

Ameritas Advisory Services LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 54.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,644 shares of the company’s stock after acquiring an additional 2,338 shares during the period. Ameritas Advisory Services LLC’s holdings in Eli Lilly and Company were worth $5,069,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of LLY. Dash Acquisitions Inc. lifted its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock valued at $387,000 after buying an additional 13 shares during the last quarter. Nvest Financial LLC raised its position in Eli Lilly and Company by 0.6% during the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after acquiring an additional 13 shares in the last quarter. MPS Loria Financial Planners LLC raised its position in Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock valued at $545,000 after acquiring an additional 13 shares in the last quarter. Key Client Fiduciary Advisors LLC lifted its stake in Eli Lilly and Company by 1.2% in the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock valued at $867,000 after acquiring an additional 13 shares during the last quarter. Finally, Darwin Wealth Management LLC grew its position in Eli Lilly and Company by 3.6% in the third quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.3%

LLY opened at $1,038.59 on Friday. The business has a 50 day moving average of $1,051.78 and a 200-day moving average of $904.70. The stock has a market capitalization of $981.86 billion, a price-to-earnings ratio of 45.25, a P/E/G ratio of 1.18 and a beta of 0.39. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 26.14%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LLY shares. CICC Research raised their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Leerink Partners raised their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, TD Cowen upped their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,217.71.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Robust fundamentals and guidance — Lilly reported a strong Q4 beat and raised FY2026 outlook, underscoring surging GLP‑1/weight‑loss revenue and underpinning investor optimism. How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
• Positive Sentiment: Pre‑launch inventory build — Lilly filed that it has about $1.5 billion of pre‑launch inventory for its experimental oral weight‑loss pill, signaling management confidence in commercialization and readiness to capture market share if approved. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Positive Sentiment: M&A to expand pipeline — Lilly agreed to acquire Orna Therapeutics for up to $2.4B, adding an RNA platform that diversifies growth beyond GLP‑1s and supports longer‑term R&D optionality. Eli Lilly to acquire ‘world’s most innovative biotech startup’ for up to $2.4B
• Positive Sentiment: Analyst upgrades & institutional buying — recent upgrades (Freedom Capital to strong‑buy) and a stake increase by Fisher Asset Management reinforce buy‑side conviction. Zacks / analyst coverage
• Neutral Sentiment: Industry tailwinds from AI and biotech momentum — broader analyst pieces highlight AI drug‑discovery and biotech sector strength that could benefit Lilly longer term, but these are thematic rather than company‑specific catalysts. 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
• Neutral Sentiment: Market commentary and price forecasts — multiple outlets publish bullish multi‑year forecasts and “reasons to buy” writeups; useful for sentiment but speculative for near‑term price moves. Stock Price Prediction and Forecast 2026-2030
• Negative Sentiment: Regulatory binary risk — the April FDA decision on the oral weight‑loss pill is binary and could trigger significant volatility; the large pre‑launch build increases both upside on approval and downside on rejection or delays. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Negative Sentiment: Competitive dynamics — Novo Nordisk remains a dominant competitor in obesity drugs; market‑share battles, pricing pressure or faster rival launches could blunt Lilly’s growth trajectory. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.